Glenmark's Lead Compound For COPD Fails; Forest To Wait For 2010 Studies In Asthma Patients
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Hopes of a novel drug to treat smoking-induced lung disease were dashed after India's Glenmark Pharma and its U.S.-based research partner Forest Labs announced that the compound under development in Phase IIb human trials failed to meet efficacy endpoints
You may also be interested in...
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
MUMBAI - After a prolonged decision-making process, India's Glenmark Pharmaceuticals is likely to halt development of potential compounds melogliptin (GRC 8200) and pain management drug GRC 6211